1-phenyl-1,4-epoxy-1H,4H-naphtho<1,8-de><1,2>dioxepine | 127064-91-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 萘
• 英文名称: 1-phenyl-1,4-epoxy-1H,4H-naphtho<1,8-de><1,2>dioxepine
• 英文别名: 1-phenyl-1,4-epoxy-1H,4H-naphtho[1,8-de][1,2]dioxepin；1-phenyl-1,4-epoxy-1H,4H-naphtho(1,8-de)[1,2]dioxepine；10-phenyl-11,12,15-trioxatetracyclo[7.4.1.110,13.05,14]pentadeca-1,3,5(14),6,8-pentaene
• CAS: 127064-91-9
• 化学式: C₁₈H₁₂O₃
• 分子量: 276.291
• InChiKey: RWQOKFNYMOMEBR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  27.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  1-acetyl-8-<(ethoxycarbonyl)vinyl>naphthalene 在 臭氧 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 生成 1-phenyl-1,4-epoxy-1H,4H-naphtho<1,8-de><1,2>dioxepine
  参考文献：
  名称：

  Ozonolysis of acenaphthylene and 1-substituted acenaphthylenes

  摘要：

  DOI：

  10.1021/jo00299a024

文献信息

• Ozonide compounds with inhibitory activity for urokinase production and angiogenesis
  申请人：Taiho Pharmaceutical Company Ltd.

  公开号：US06365610B1

  公开（公告）日：2002-04-02

  The invention provides a urokinase production inhibitor or angiogenesis inhibitor comprising as an active component an ozonide derivative represented by the formula (1), and method of prevention or therapy using the inhibitor wherein A is an oxygen atom or N—R (wherein R is phenyl or phenyl having as a substituent lower alkyl having 1 to 6 carbon atoms, lower alkoxyl having 1 to 6 carbon atoms or a halogen atom); B is an oxo group or —R4; and (1) when A is an oxygen atom, R1 is a hydrogen atom, etc., R2 is phenyl, etc., R3 is a hydrogen atom, etc., B is an oxo group or —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.; (2) when A is N—R, R1 is a hydrogen atom, etc., R2 is a hydrogen atom, etc., R3 is a hydrogen atom, etc., B is —R4, R4 is a hydrogen atom, etc., R5 is a hydrogen atom, etc.

  该发明提供了一种尿激酶产生抑制剂或血管生成抑制剂，其包括作为活性成分的一种由式（1）表示的臭氧化物衍生物，以及使用该抑制剂的预防或治疗方法，其中A是氧原子或N—R（其中R是苯基或苯基，其取代基为1至6个碳原子的较低烷基，1至6个碳原子的较低烷氧基或卤原子）；B是羰基或—R4；当A是氧原子时，R1是氢原子等，R2是苯基等，R3是氢原子等，B是羰基或—R4，R4是氢原子等，R5是氢原子等；当A是N—R时，R1是氢原子等，R2是氢原子等，R3是氢原子等，B是—R4，R4是氢原子等，R5是氢原子等。
• McCullough, Kevin J.; Sugimoto, Toshiya; Tanaka, Shogo, Journal of the Chemical Society. Perkin transactions I, 1994, # 6, p. 643 - 652
  作者：McCullough, Kevin J.、Sugimoto, Toshiya、Tanaka, Shogo、Kusabayashi, Shigekazu、Nojima, Masatomo

  DOI：——

  日期：——
• Sugimoto, Toshiya; Nojima, Masatomo; Kusabayashi, Shigekazu, Journal of the American Chemical Society, 1990, vol. 112, # 9, p. 3690 - 3692
  作者：Sugimoto, Toshiya、Nojima, Masatomo、Kusabayashi, Shigekazu、McCullough, Kevin J.

  DOI：——

  日期：——
• INHIBITOR OF UROKINASE PRODUCTION AND OF ANGIOGENESIS AND ITS THERAPEUTIC USE
  申请人：TAIHO PHARMACEUTICAL COMPANY LIMITED

  公开号：EP1033130B1

  公开（公告）日：2004-04-21
• Methods and Therapeutic Compositions Comprising Plant Extracts for the Treatment of Cancer
  申请人：Cyr Benoit

  公开号：US20090004302A1

  公开（公告）日：2009-01-01

  A method of treating cancer by targeting two proteases, MMP-9 and cathepsin B is provided. Therapeutic compositions comprising one or more plant extracts that inhibit MMP-9 and/or cathepsin B, which are capable of inhibiting neoplastic and/or endothelial cell migration, tumour growth, tumour-induced angiogenesis and/or metastasis are also provided. The therapeutic compositions of the invention can be used in the treatment of cancer, and, methods of inhibiting tumour growth, tumour metastasis, and/or tumour-induced angiogenesis using the therapeutic compositions alone or in combination with an anti-cancer agent are, therefore, also provided.